ReviewMedical gas research2026
Gas therapy: an innovative application for intervertebral disc degeneration.
Review in Medical gas research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resetting the epigenetic clock: cellular senescence and regenerative strategies in intervertebral disc degeneration.Frontiers in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Environmental gaseous molecules extensively participate in human physiological and pathological regulation through differential biological effects. Gas transmitter-based therapeutic strategies, as emerging intervention modalities, have demonstrated significant translational value in intervertebral disc degeneration management. The intervertebral disc degeneration susceptibility to progressive degenerative pathology stems from its unique avascular nature and complex biomechanical microenvironment, while conventional therapies face limitations in efficacy and carry invasive risks. This review systematically delineates innovative applications of gaseous therapeutics for intervertebral disc degeneration, encompassing clinically established ozone and hyperbaric oxygen therapies alongside preclinical-stage hydrogen, hydrogen sulfide, and nitric oxide interventions. Comprehensive analyses address molecular properties, biological functions, and mechanistic actions. Current evidence indicates that gas therapies significantly alleviate pain and improve functional impairment through targeted modulation of oxidative stress-inflammation-apoptosis cascades and extracellular matrix metabolic dysregulation. Their minimally invasive precision delivery capabilities and multimodal bio-regulatory advantages offer groundbreaking diagnostic and therapeutic strategies for intervertebral disc degeneration, exhibiting well-defined clinical translation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.